JP2018518485A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518485A5
JP2018518485A5 JP2017563292A JP2017563292A JP2018518485A5 JP 2018518485 A5 JP2018518485 A5 JP 2018518485A5 JP 2017563292 A JP2017563292 A JP 2017563292A JP 2017563292 A JP2017563292 A JP 2017563292A JP 2018518485 A5 JP2018518485 A5 JP 2018518485A5
Authority
JP
Japan
Prior art keywords
polypeptide
peg
pharmaceutical composition
lipid
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017563292A
Other languages
English (en)
Japanese (ja)
Other versions
JP6811190B2 (ja
JP2018518485A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/063206 external-priority patent/WO2016198544A1/en
Publication of JP2018518485A publication Critical patent/JP2018518485A/ja
Publication of JP2018518485A5 publication Critical patent/JP2018518485A5/ja
Application granted granted Critical
Publication of JP6811190B2 publication Critical patent/JP6811190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017563292A 2015-06-10 2016-06-09 プロテアーゼ耐性脂質付加ｇｌｐ−１類似体 Active JP6811190B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562173631P 2015-06-10 2015-06-10
US62/173,631 2015-06-10
US201662343390P 2016-05-31 2016-05-31
US62/343,390 2016-05-31
PCT/EP2016/063206 WO2016198544A1 (en) 2015-06-10 2016-06-09 Protease-resistant lipidated glp-1 analogs

Publications (3)

Publication Number Publication Date
JP2018518485A JP2018518485A (ja) 2018-07-12
JP2018518485A5 true JP2018518485A5 (https=) 2019-05-23
JP6811190B2 JP6811190B2 (ja) 2021-01-13

Family

ID=56235790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017563292A Active JP6811190B2 (ja) 2015-06-10 2016-06-09 プロテアーゼ耐性脂質付加ｇｌｐ−１類似体

Country Status (25)

Country Link
US (3) US10414811B2 (https=)
EP (2) EP3307769B1 (https=)
JP (1) JP6811190B2 (https=)
KR (1) KR20180016441A (https=)
CN (1) CN108271373B (https=)
AU (2) AU2016277449B2 (https=)
CA (1) CA2988841C (https=)
CL (1) CL2017003144A1 (https=)
CO (1) CO2017012675A2 (https=)
CR (1) CR20170559A (https=)
DO (1) DOP2017000287A (https=)
EA (1) EA036415B1 (https=)
ES (1) ES2849950T3 (https=)
IL (1) IL255978B (https=)
MX (1) MX389407B (https=)
MY (1) MY185816A (https=)
NI (1) NI201700156A (https=)
NZ (1) NZ738909A (https=)
PE (1) PE20180659A1 (https=)
PH (1) PH12017502259A1 (https=)
SG (1) SG10201911837SA (https=)
SV (1) SV2017005585A (https=)
TN (1) TN2017000519A1 (https=)
TW (1) TWI726889B (https=)
WO (1) WO2016198544A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018014966A (es) * 2016-06-09 2019-08-14 Medimmune Ltd Peptidos monolipidados resistentes a proteasas.
CN111655338A (zh) * 2017-10-31 2020-09-11 免疫医疗有限公司 Glp-1肽类似物的口服递送
MX2020010505A (es) 2018-04-05 2021-01-15 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1.
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JP2006501820A (ja) 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
CN101010339B (zh) * 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
US8318668B2 (en) * 2005-09-08 2012-11-27 Trustees Of Tufts College Stabilized GLP-1 analogs
EP1854455B1 (en) * 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
CA2707448C (en) 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
EP2364326B1 (en) * 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
WO2011048614A2 (en) 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
MX2012013001A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
US20130143800A1 (en) 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
JP2016506391A (ja) 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法
CA2902352A1 (en) * 2013-03-14 2014-09-18 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
CN105849123A (zh) 2013-12-13 2016-08-10 免疫医疗有限公司 蛋白酶抗性肽

Similar Documents

Publication Publication Date Title
JP2018518485A5 (https=)
JP6229038B2 (ja) 修飾された血管作動性腸管ペプチド
JP2011526303A5 (https=)
CN103003300B (zh) Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
JP2025093970A (ja) インクレチン類似体およびその使用
JP2007001987A5 (https=)
AU2017371516A1 (en) Acylated GLP-1/GLP-2 dual agonists
JP2018135346A5 (https=)
RU2007134155A (ru) Glp-1 соединения с увеличенным временем полужизни
TWI353250B (en) Glp-1 pharmaceutical compositions
JP2004501162A (ja) グルカゴン様ペプチド−１類似体
CN105263957A (zh) 治疗肽
CN101213209A (zh) 新颖化合物及它们对进食行为的影响
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
BRPI1008061B1 (pt) Polipeptídeos recombinantes estendidos (xten), proteína de fusão isolada compreendendo os mesmos e método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
JP2013515057A5 (https=)
AU2017373901A1 (en) GLP-1/GLP-2 dual agonists
WO2008056726A1 (en) Glp-1 derivative and use thereof
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP6811190B2 (ja) プロテアーゼ耐性脂質付加ｇｌｐ−１類似体
JP2010174016A (ja) Ｇｌｐ−１類似体
CN106255701A (zh) 可从前胰高血糖素原衍生出的肽激素类似物
JP2007524579A (ja) Ｇｌｐ−１の類似体
CN105801705A (zh) 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途
WO2024067662A1 (zh) Glp-1/gcg/gip三受体激动剂及其用途